Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis

Journal of Clinical Investigation

Volumn 116, Issue 4, 2006, Pages 984-995

  Thimmulappa, Rajesh K ^a   Lee, Hannah ^a   Rangasamy, Tirumalai ^a   Reddy, Sekhar P ^a   Yamamoto, Masayuki ^a,b   Kensler, Thomas W ^a,c   Biswal, Shyam ^a,c,d,e  

^a Johns Hopkins University   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GLUTATHIONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE DYSREGULATION; INNATE IMMUNITY; MALE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; STRESS; SURVIVAL RATE;

ANIMALS; ANTIOXIDANTS; CECUM; CELL ADHESION MOLECULES; CHEMOKINES; IMMUNITY, NATURAL; LIPOPOLYSACCHARIDES; MALE; MICE; NF-E2-RELATED FACTOR 2; PNEUMONIA; RECEPTORS, CELL SURFACE; SEPSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645530745     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25790     Document Type: Article

References (45)

1. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature. 420:885-891.
2. Pinsky, M.R. 2004. Dysregulation of the immune response in severe sepsis. Am. J. Med. Sci. 328:220-229.
3. Angus, D.C., et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
4. Arcaroli, J., Fessler, M.B., and Abraham, E. 2005. Genetic polymorphisms and sepsis. Shock. 24:300-312.
5. Thimmulappa, R.K., et al. 2002. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62:5196-5203.
6. Kwak, M.K., et al. 2003. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278:8135-8145.
7. Rangasamy, T., et al. 2004. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114:1248-1259. doi:10.1172/JCI200421146.
8. Motohashi, H., and Yamamoto, M. 2004. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10:549-557.
9. Jain, A.K., Bloom, D.A., and Jaiswal, A.K. 2005. Nuclear import and export signals in control of NRF2. J. Biol. Chem. 280:29158-29168.
10. Velichkova, M., and Hasson, T. 2005. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell. Biol. 25:4501-4513.
11. Ramos-Gomez, M., et al. 2001. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98:3410-3415.
12. Rangasamy, T., et al. 2005. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 202:47-59.
13. Chignard, M., and Balloy, V. 2000. Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. Am. J. Physiol. Lung Cell. Mol. Physiol. 279:L1083-L1090.
14. Eskandari, M.K., et al. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
15. Dziarski, R., Platt, K.A., Gelius, E., Steiner, H., and Gupta, D. 2003. Defect in neutrophil killing and increased susceptibility to infection with non-pathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. Blood. 102:689-697.
16. Riedemann, N.C., et al. 2002. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110:101-108. doi:10.1172/JCI200421146.
17. Mori, M., and Gotoh, T. 2004. Arginine metabolic enzymes, nitric oxide and infection. J. Nutr. 134:2820S-2825S; discussion 2853S.
18. Terness, P., et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447-457.
19. Brumell, J.H., et al. 1999. Expression of the protein kinase C substrate pleckstrin in macrophages: association with phagosomal membranes. J. Immunol. 163:3388-3395.
20. Blackwell, T.S., and Christman, J.W. 1997. The role of nuclear factor-kappa B in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 17:3-9.
21. Doyle, S., et al. 2002. IRF3 mediates a TLR3/ TLR4-specific antiviral gene program. Immunity. 17:251-263.
22. Yamamoto, M., et al. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301:640-643.
23. Akira, S., and Takeda, K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.
24. Hoshino, K., et al. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749-3752.
25. Poltorak, A., et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:2085-2088.
26. McCartney-Francis, N., Jin, W., and Wahl, S.M. 2004. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J. Immunol. 172:3814-3821.
27. Grivennikov, S.I., et al. 2005. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity. 22:93-104.
28. Mathison, J.C., Wolfson, E., and Ulevitch, R.J. 1988. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Invest. 81:1925-1937.
29. Beutler, B., Milsark, I.W., and Cerami, A.C. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:869-871.
30. Covert, M.W., Leung, T.H., Gaston, J.E., and Baltimore, D. 2005. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science. 309:1854-1857.
31. Leturcq, D.J., et al. 1996. Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Invest. 98:1533-1538.
32. Fitzgerald, K.A., et al. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491-496.
33. Hemmi, H., et al. 2004. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199:1641-1650.
34. Janssen-Heininger, Y.M., Poynter, M.E., and Baeuerle, P.A. 2000. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic. Biol. Med. 28:1317-1327.
35. Asehnoune, K., Strassheim, D., Mitra, S., Kim, J.Y., and Abraham, E. 2004. Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF-kappaB. J. Immunol. 172:2522-2529.
36. Sanlioglu, S., et al. 2001. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J. Biol. Chem. 276:30188-30198.
37. Asehnoune, K., Strassheim, D., Mitra, S., Kim, J.Y., and Abraham, E. 2004. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J. Immunol. 172:2522-2529.
38. Ardite, E., Barbera, J.A., Roca, J., and Fernandez-Checa, J.C. 2004. Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-kappaB activation. Am. J. Pathol. 165:719-728.
39. Mirochnitchenko, O., et al. 2000. Endotoxemia in transgenic mice overexpressing human glutathione peroxidases. Circ. Res. 87:289-295.
40. Suh, J.H., et al. 2004. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 101:3381-3386.
41. Itoh, K., et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:313-322.
42. Zisman, D.A., et al. 1997. MCP-1 protects mice in lethal endotoxemia. J. Clin. Invest. 99:2832-2836.
43. Speyer, C.L., et al. 2003. Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am. J. Pathol. 163:2319-2328.
44. Sasaki, H., et al. 2002. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277:44765-44771.
45. Tirumalai, R., Rajesh Kumar, T., Mai, K.H., and Biswal, S. 2002. Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Toxicol. Lett. 132:27-36.